In light of recent work illuminating prognostic roles for immune-related genes in specific pathological contexts such as ER- or HER2+ breast cancer [17,30,32,33], we asked whether the prognostic performance of the immune metagenes was exclusive to the high proliferation tertile in specific tumor subtypes (Table 5). This evidence concerns the gene ESR1 and breast carcinoma.